Annovis' Alzheimer's treatment helps improve cognition in trial (updated)

Annovis Bio

29/04/2024 15:51

(Adds further details in paragraphs 2 and 3)
       April 29 (Reuters) - 
    Annovis Bio  ANVS.N  said on Monday its Alzheimer's
treatment showed significantly higher improvement in cognition
in patients during a mid-stage trial.
    The company's drug buntanetap works by decreasing the
production of amyloid beta protein, believed to be a hallmark of
Alzheimer's, from the brain.
        Annovis plans to conduct a late-stage trial based on
results of this trial.
  

 (Reporting by Christy Santhosh; Editing by Vijay Kishore)
 ((Christy.Santhosh@thomsonreuters.com;))